Gold prices bounce off 3-week lows; demand likely longer term
GUILDFORD, UK - ANGLE plc (AIM:AGL OTCQX:ANPCY), a liquid biopsy company, announced Monday that shareholders approved all resolutions presented at its Annual General Meeting.
The company, which specializes in circulating tumor cell (CTC) technology, held its yearly shareholder meeting earlier in the day. While specific voting details were not immediately disclosed, the company stated that complete voting information would be made available on its corporate website.
ANGLE’s primary technology is the Parsortix PC1 System, an FDA-cleared device designed to harvest circulating tumor cells from blood samples for subsequent analysis. The system enables various downstream analytical processes including imaging, proteomic, genomic, and transcriptomic examinations.
The company operates two main commercial divisions focused on clinical services and diagnostic products. Its clinical services are provided through laboratories that comply with Good Clinical Laboratory Practice (GCLP) standards, offering custom assay development and clinical trial testing for pharmaceutical companies. The product division markets the Parsortix system along with related consumables and assays.
According to the press release statement, ANGLE’s technology has been featured in over 100 peer-reviewed publications demonstrating the system’s performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.